Consensus RemeGen Co., Ltd.

Equities

9995

CNE1000048G6

Market Closed - Hong Kong S.E. Other stock markets 03:59:31 2024-05-09 am EDT			5-day change	1st Jan Change
32.15 ^HKD	+0.63%		+7.17%	-14.15%

Apr. 26	RemeGen Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 04	Remegen Gets US FDA Fast Track Designation for Primary Sjögren's Syndrome Medication	MT

Evolution of the average Target Price on RemeGen Co., Ltd.

Price target over the last 5 years

History of analyst recommendation changes

5d23821b834b409a0a.USVgadhsKEN5jewhIXyRgtNB7MqsnDeCYSStYII197M.GBQDPK4BY3A34LhbTRD71b4A3__67ViyLmDiIa9_qMAdchU9r1p_GRvmtQ~82a883999c473c03e043988fb7a51e0b

Analyst Recommendations on RemeGen Co., Ltd.

UBS Adjusts RemeGen's Price Target to HK$75.20 From HK$75.03, Keeps at Buy	22-09-02	MT
UBS Upgrades RemeGen to Buy From Neutral, Adjusts Price Target to HK$75.03 From HK$108	22-04-11	MT